NCT06693336View on ClinicalTrials.gov

An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

November 18, 2024

Primary Completion Date

October 30, 2025

Study Completion Date

October 30, 2026

Conditions
Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)
Interventions
DRUG

SMS001

One time administration

Trial Locations (1)

M5G 2C4

RECRUITING

Toronto General Hospital, Toronto

Sponsors
All Listed Sponsors
collaborator

Ozmosis Research Inc.

INDUSTRY

collaborator

University Health Network (UHN)

UNKNOWN

collaborator

Mayo Clinic

OTHER

lead

ToLymph Inc.

INDUSTRY